Organon (OGN) Other Non-Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Other Non-Current Liabilities of $1.0 billion for Q2 2026, down 8.47% year-over-year from $1.1 billion in Q2 2025, and up 4.27% on a QoQ basis from $984.0 million in Q1 2026.
Organon (OGN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon has reported Other Non-Current Liabilities for 7 years, with the latest figure at $1.0 billion in Q2 2026.
- Other Non-Current Liabilities for Q2 2026 came in at $1.0 billion, down 8.47% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 8.47% YoY), and the FY2025 annual result was $1.0 billion, up 3.17% from the prior year.
- Other Non-Current Liabilities advanced to $1.0 billion in Q2 2026, from $984.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.1 billion in Q3 2025 and troughed at $393.0 million in Q2 2023.
- A 5-year average of $689.1 million and a median of $548.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities sank 75.42%; it then soared 137.14% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $411.0 million in 2022, then increased by 0.24% to $412.0 million in 2023, then soared by 137.14% to $977.0 million in 2024, then advanced by 3.17% to $1.0 billion in 2025, then grew by 1.79% to $1.0 billion in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.0 billion in Q2 2026, $984.0 million in Q1 2026, and $1.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 984.00 Mn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.12 Bn |
| Mar 31, 2025 | 994.00 Mn |
| Dec 31, 2024 | 977.00 Mn |
| Sep 30, 2024 | 674.00 Mn |
| Jun 30, 2024 | 548.00 Mn |
| Mar 31, 2024 | 549.00 Mn |
| Dec 31, 2023 | 412.00 Mn |
| Sep 30, 2023 | 421.00 Mn |
| Jun 30, 2023 | 393.00 Mn |
| Mar 31, 2023 | 421.00 Mn |
| Dec 31, 2022 | 411.00 Mn |
| Sep 30, 2022 | 441.00 Mn |
| Jun 30, 2022 | 448.00 Mn |
| Mar 31, 2022 | 454.00 Mn |
| Dec 31, 2021 | 463.00 Mn |
| Sep 30, 2021 | 506.00 Mn |